Y-mAbs TherapeuticsYMAB Market cap $631M
About: Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Employees: 100
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
8,125% more call options, than puts
Call options by funds: $329K | Put options by funds: $4K
2.52% more ownership
Funds ownership: 52.98% [Q1] → 55.5% (+2.52%) [Q2]
0% more funds holding
Funds holding: 95 [Q1] → 95 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
3% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 35
22% less capital invested
Capital invested by funds: $377M [Q1] → $294M (-$82.8M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Wedbush David Nierengarten 45% 1-year accuracy 15 / 33 met price target | 62%upside $23 | Outperform Reiterated | 10 Sept 2024 |
Cantor Fitzgerald Li Watsek 48% 1-year accuracy 12 / 25 met price target | 41%upside $20 | Overweight Reiterated | 9 Sept 2024 |
Cantor Fitzgerald Li Watsek 48% 1-year accuracy 12 / 25 met price target | 41%upside $20 | Overweight Initiated | 16 Aug 2024 |
Canaccord Genuity Bill Maughan 55% 1-year accuracy 6 / 11 met price target | 84%upside $26 | Buy Maintained | 13 Aug 2024 |
Morgan Stanley Michael Ulz 27% 1-year accuracy 3 / 11 met price target | 22%downside $11 | Underweight Maintained | 13 Aug 2024 |